Microencapsulated Genetically EngineeredLactobacillus plantarum80 (pCBH1) for BileAcid Deconjugation and Its Implicationin Lowering Cholesterol

[摘要] Cholesterol is known to be a major risk factor for coronary heartdisease (CHD). Current treatments for elevated blood cholesterolinclude dietary management, regular exercise, and drug therapywith fibrates, bile acid sequestrants, and statins. Suchtherapies, however, are often suboptimal and carry a risk forserious side effects. This study shows that microencapsulatedLactobacillus plantarum80 (pCBH1) cells can efficientlybreak down and remove bile acids, and establishes a basis fortheir use in lowering blood serum cholesterol. Results show thatmicroencapsulated LP80 (pCBH1) is able to effectively break downthe conjugated bile acids glycodeoxycholic acid (GDCA) andtaurodeoxycholic acid (TDCA) with bile salt hydrolase (BSH)activities of 0.19 and 0.08μmol DCA/mg CDW/hrespectively. This article also summarizes the physiologicalinterrelationship between bile acids and cholesterol and predictsthe oral doses of microencapsulatedLactobacillusplantarum80 (pCBH1) cells required for lowering cholesterol.

[学科分类] 基础医学